Elan (ELN) Restructures Tysabri Collaboration w/ Biogen (BIIB); Will Get $3.25B Upfront
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow up on UnitedHealth boost; higher bond yields, Mideast tensions cap gains
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- BofA profit hurt by provisions even as it expects rising interest income
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
RBC Capital Downgrades Elan Corp (ELN) to Sector Perform
February 7, 2013 9:15 AM ESTRBC Capital downgraded Elan Corp (NYSE: ELN) from Outperform to Sector Perform with a price target of $11.00 (from $15.00) following sale of Tysabri rights.
For an analyst ratings summary and ratings history on Elan Corp... More
Deutsche Bank Boosts PT on Biogen (BIIB) to $170 on Tysabri Deal
February 6, 2013 3:50 PM ESTDeutsche Bank raised its price target on Buy-rated Biogen (NASDAQ: BIIB) from $160 to $170 following the news the company acquired 100% rights for Tysabri from ELAN (NYSE: ELN) for an upfront payment of $3.25B and contingent royalty payments based... More
Deutsche Bank Downgrades Elan Corp (ELN) to Hold; Post Tysabri Deal M&A Activity in Focus
February 6, 2013 3:46 PM ESTDeutsche Bank downgraded Elan Corp (NYSE: ELN) from Buy to Hold with a EUR 7.60 price target following the sale of Tysabri to Biogen.
The firm comments, "Elans decision to cede control of Tysabri to Biogen seems to be an attractive... More
